Skip to main content
SpringerLink
Log in

Anticonvulsant Agents: Lacosamide and Perampanel

  • Living reference work entry
  • First Online:
NeuroPsychopharmacotherapy

  • 36 Accesses

Abstract

The treatment of epilepsy has been largely improving in the last 30 years especially due to the introduction of the second generation of anticonvulsants, the so called new anticonvulsive drugs consisting of a group of newly admitted anticonvulsant agents with various pharmacological profiles (Baumgartner and Elger). Among them, lacosamide and perampanel belong to the important choice in the treatment of difficult-to-treat epilepsies according to their broad spectrum of action and good clinical tolerability, which will be individually discussed in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Abou-Khalil BW. Lacosamide: what can be expected from the next new antiepileptic drug? Epilepsy Curr. 2009;9(5):133–4.

    Article  PubMed  PubMed Central  Google Scholar 

  • Baulac M, Rosenow F, Toledo M, Terada K, Li T, De Backer M, Werhahn K, Brock M. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2017;16(1):43–54.

    Article  CAS  PubMed  Google Scholar 

  • Ben-Menachem E, Biton V, Jatuzis D, AbouKhalil B, Doty P, Rudd G. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48:1308–17.

    Article  CAS  PubMed  Google Scholar 

  • Beyreuther B, Freitag J, Heers C, Krebsfänger N, Scharfenecker U, Stöhr T. Lacosamide: a review of preclinical properties. CNS Drug Rev. 2007;13(1):21–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cawello W. Clinical pharmacokinetic and pharmacodynamic profile of lacosamide. Clin Pharmacokinet. 2015;54:901–14.

    Article  CAS  PubMed  Google Scholar 

  • Cawello W, Bonn R. No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers. J Clin Pharmacol. 2012;52:1739–48.

    Article  CAS  PubMed  Google Scholar 

  • Cawello W, Nickel B, Eggert-Formella A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Pharmacol. 2010;50:459–71.

    Article  CAS  PubMed  Google Scholar 

  • Cawello W, Bonn R, Boekens H. Bioequivalence of intravenous and oral formulations of the antiepileptic drug lacosamide. Pharmacology. 2012a;90:40–6.

    Article  CAS  PubMed  Google Scholar 

  • Cawello W, Boekens H, Bonn, R. Absorption, disposition, metabolic fate and S Bauer, LM Willems et al. http://tan.sagepub.com 123 elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration. Eur J Drug Metab Pharmacokinet. 2012b;37:241–248.

  • Cawello W, Rosenkranz B, Schmid B, Wierich W. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. Epilepsia. 2013;54:530–6.

    Article  CAS  PubMed  Google Scholar 

  • Cawello W, Mueller-Voessing C, Fichtner A. Pharmacokinetics of lacosamide and omeprazole coadministration in healthy volunteers: results from a phase I, randomized, crossover trial. Clin Drug Investig. 2014a;34:317–25.

    Article  CAS  PubMed  Google Scholar 

  • Cawello W, Stockis A, Andreas J, Dimova S. Advances in epilepsy treatment: lacosamide pharmacokinetic profile. Ann N Y Acad Sci. 2014b;1329:18–32.

    Article  CAS  PubMed  Google Scholar 

  • Ceolin L, Bortolotto ZA, Bannister N, Collingridge GL, Lodge D, Volianskis A. A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor mediated synaptic transmission in the hippocampus. Neurochem Int. 2012;61:517–22.

    Article  CAS  PubMed  Google Scholar 

  • Chung S, Sperling M, Biton V, Krauss G, Hebert D, Rudd G, Doty P. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010;51:958–67.

    Article  CAS  PubMed  Google Scholar 

  • Doty P, Rudd GD, Stoehr T, Thomas D. Lacosamide. Neurotherapeutics. 2007;4(1):145–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Doty P, Herbert D, Mathy FX, Byrnes W, Zackheim J, Simontacchi K. Development of lacosamide for the treatment of partial-onset seizures. Ann N Y Acad Sci. 2013;1291(1):56–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • European Medicines Agency EMA. Fycompa - EMEA/H/C/002434 - II/0047. Available at: https://www.ema.europa.eu/en/documents/product-information/fycompa-epar-product-information_en.pdf

  • European Medicines Agency EMA. Vimpat 29/01/2021. Available at: https://www.ema.europa.eu/en/documents/product-information/fycompa-epar-product-information_en.pdf

  • French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, Kumar D, Rogawski MA. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79:589–96.

    Article  PubMed  PubMed Central  Google Scholar 

  • French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D, Laurenza A. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54:117–25.

    Article  CAS  PubMed  Google Scholar 

  • French JA, Krauss GL, Wechsler RT, Wang XF, DiVentura B, Brandt C, Trinka E, Terence J, O'Brien TJ, Laurenza A, Patten A, Bibbiani F. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial. Neurology. 2015;85(11):950–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, Rosenow F, Doty P, Hebert D, Timothy S. SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009;50:443–53.

    Article  CAS  PubMed  Google Scholar 

  • Horstmann R, Bonn R, Cawello W, et al. Basic clinical pharmacological investigation of the new antiepileptic drug SPM 927. Epilepsia. 2002;43(Suppl 7):188.

    Google Scholar 

  • Horstmann R, Bonn R, Cawello W, et al. SPM 927 does not interact with valproic acid or carbamazepine. Epilepsia. 2003;44(Supp 9):97.

    Google Scholar 

  • https://arznei-news.de/lacosamid

  • https://cnmobile.prnasia.com

  • https://news.bioon.com

  • Italiano D, Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet. 2013;52(8):627–45.

    Article  CAS  PubMed  Google Scholar 

  • Kellinghaus C, Berning S, Immisch I, Larch J, Rosenow F, Rossetti AO, Tilz C, Trinka E. Intravenous lacosamide for the treatment of status epilepticus. Acta Neurol Scand. 2011;123(2):137–41.

    Article  CAS  PubMed  Google Scholar 

  • Kellinghaus C, Rossetti AO, Trinka E, Lang N, May TW, Unterberger I, Rüegg S, Sutter R, Strzelczyk A, Tilz C, Uzelac Z, Rosenow F. Factors predicting cessation of status epilepticus in clinical practice, data from a prospective observational registry (SENSE). Ann Neurol. 2019;85(3):421–32.

    CAS  PubMed  Google Scholar 

  • Kohn H, Conley JD, Leander JD. Marked stereospecifity in a new class of anti-convulsants. Brain Res. 1988;457:371–5.

    Article  CAS  PubMed  Google Scholar 

  • Krämer G, Heinzl S. Lacosamid essenziell. Stuttgart: Ligatur; 2008.

    Google Scholar 

  • Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J, Yang H, Squillacote D, Edwards HB, Zhu J, Laurenza A. Randomized phase III study 306: adjunctive perampanel for refractory partial onset seizures. Neurology. 2012;78:1408–15.

    Article  CAS  PubMed  Google Scholar 

  • Krauss GL, Perucca E, Ben-Menachem E, Ben-Menachem E, Kwan P, Shih JJ, Clément JF, Wang XF, Bagul M, Gee M, Zhu J, Squillacote D. Long-term safety of perampanel and seizure outcomes in refractory partial onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia. 2014;55:1058–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kropeit D, Schiltmeyer B, Cawello W, Hammes W, Horstmann R. Bioequivalence of short-time infusions compared to oral administation of lacosamide. Epilepsia. 2004;45(Suppl. 7):123.

    Google Scholar 

  • Kurth C, Kockelmann E, Steinhoff BJ. Clinical outcomes of perampanel vs lacosamide in cohorts of consecutive patients with severely refractory epilepsies - A monocentric retrospective analysis of systematically collected data from the German Kork Epilepsy Center. Seizure. 2017;45:47–51.

    Article  PubMed  Google Scholar 

  • Lancman ME, Fertig EJ, Trobliger RW, Perrine K, Myers L, Iyengar SS, Munazza Malik M. The effects of lacosamide on cognition, quality-of-life measures, and quality of life in patients with refractory partial epilepsy. Epilepsy Behav. 2016;61:27–33.

    Article  PubMed  Google Scholar 

  • Legros B, Depondt C, Levy-Nogueira M, Ligot N, Mavroudakis N, Naeije G. Intravenous lacosamide in refractory seizure clusters and status epilepticus: comparison of 200 and 400 mg loading doses. Neurocrit Care. 2014;20:484–8.

    Article  CAS  PubMed  Google Scholar 

  • Meschede C, Witt J, Rademacher M, von Wrede RD, Elger C, Helmstaedter C. Evaluating the longer- term cognitive effects of adjunctive perampanel compared to lacosamide in naturalistic outpatient setting. Seizure. 2018;58:141–6.

    Article  PubMed  Google Scholar 

  • Moseley B, Cole D, Iwuora O, Strawn J, Privitera M. The effects of lacosamide on depression and anxiety in patients with epilepsy. Epilepsy Res. 2015;110:115–8.

    Article  CAS  PubMed  Google Scholar 

  • Novy J, Patsalos PN, Sander JW, Sisodiya SM. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav. 2011;20(1):20–3.

    Article  PubMed  Google Scholar 

  • Patsalos P. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015;56(1):12–27.

    Article  CAS  PubMed  Google Scholar 

  • Potschka H, Trinka E. Perampanel: does it have broad spectrum potential. Epilepsia. 2019;60(Suppl 1):22–36.

    Article  CAS  PubMed  Google Scholar 

  • Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective noncompetitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013;197:19–24.

    Article  CAS  Google Scholar 

  • Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, Squillacote D, Zhu J, , Laurenza A. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia 2013; 54:1481–1489.

    Article  CAS  PubMed  Google Scholar 

  • Stephen LJ, Wishart A, Brodie MJ. Psychiatric side effects and antiepileptic drugs: observations from prospective audits. Epilepsy Behav. 2017;71(Pt A):73–8.

    Article  PubMed  Google Scholar 

  • Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects. https://clinicaltrials.gov/ct2/show/NCT03376997

  • Sutter R, Marsch S, Ruegg S. Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study. CNS Drugs. 2013;27:321–9.

    Article  CAS  PubMed  Google Scholar 

  • Tilz C, Resch R, Hofer T, Eggers C. Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide. Epilepsia. 2010;51(2):316–7.

    Article  CAS  PubMed  Google Scholar 

  • Traub RD, Miles R, Jefferys JG. Synaptic and intrinsic conductances shape picrotoxin-induced synchronized after-discharges in the guinea-pig hippocampal slice. J Physiol. 1993;461:525–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Trinka E, Höfler J, Leitinger M, Brigo F. Drugs. 2015;75(13):1499–521.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vossler DG. UCB: UCB's VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy. News release. UCB. November 17, 2020. Accessed November 17, 2020.

    Google Scholar 

  • Vossler DG, Knake S, O'Brien TJ, Watanabe M, Brock M, Steiniger-Brach B, Williams P, Roebling R. SP0982 trial investigators: efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised placebocontrolled trial. J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1067–75.

    Article  PubMed  Google Scholar 

  • Wechsler R, Li G, French J, O’brien T, D’cruz O, Williams P, Goodson R, Brock M. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study. Epilepsia. 2014;55:1088–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zilles K, Qü MS, Köhling R, Speckmann EJ. Ionotropic glutamate and GABA receptors in human epileptic neocortical tissue: quantitative in vitro receptor autoradiography. Neuroscience. 1999;94:1051–61.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Epilepsy Unit, Department of Neurology, Hospital of Barmherzige Brüder, Regensburg, Germany

    Christian Tilz

Authors
  1. Christian Tilz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Tilz .

Editor information

Editors and Affiliations

  1. Dept Psychiatry , Psychosomatics & Psychotherapy, University of Würzburg, Medical School Clinical Neurochemistry, Würzburg, Germany

    Peter Riederer

  2. Inst für Psychologische Medizin, Haag, Bayern, Germany

    Gerd Laux

  3. Fujita Health University School Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Würzburg, Bayern, Germany

    Christian Riederer

Section Editor information

  1. Beta Neurology – Competence Center for Epilepsy, Beta Klinik GmbH, Bonn, Germany

    Christian E. Elger FRCP

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Tilz, C. (2021). Anticonvulsant Agents: Lacosamide and Perampanel. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_449-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56015-1_449-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56015-1

  • Online ISBN: 978-3-319-56015-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation